Evonile Pharma Ltd files unaudited Q2 FY27 and H1 financial statements for the period ended September 30, 2026
- Filing includes a limited review report; the extract provides no revenue, margin, profit or growth figures.
- Reported total financial indebtedness of ₹800, with no loan default.
- Half-year related-party transaction disclosures were included.